105 Kodiak Sciences Inc. Consolidated Balance Sheets (in thousands, except share and per share amounts) December 31, 2018 December 31, 2017 Assets Current assets: Cash and cash equivalents ...................................................................................... $ 88,254 $ 1,395 Prepaid expenses and other current assets .............................................................. 2,195 200 Total current assets............................................................................................ 90,449 1,595 Restricted cash.............................................................................................................. 140 140 Property and equipment, net......................................................................................... 1,097 1,509 Other assets .................................................................................................................. 503 — Total assets ........................................................................................................ $ 92,189 $ 3,244 Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) Current liabilities: Accounts payable.................................................................................................... $ 1,050 $ 3,356 Accrued and other current liabilities....................................................................... 3,776 5,802 Total current liabilities ...................................................................................... 4,826 9,158 Convertible notes (includes $7,937 at December 31, 2017 due to related parties)...... — 9,921 Redeemable convertible preferred stock warrant liability (includes $1,840 at December 31, 2017 attributable to warrants held by related parties)........................ — 2,300 Other liabilities............................................................................................................. 530 586 Total liabilities................................................................................................... 5,356 21,965 Commitments and contingencies (Note 7) Redeemable convertible preferred stock, $0.0001 par value, 10,000,000 and 18,753,595 shares authorized at December 31, 2018 and 2017; 0 and 12,385,154 shares issued and outstanding at December 31, 2018 and 2017; liquidation value of $0 and $50,324 at December 31, 2018 and 2017 ........................................................................................................... — 50,017 Stockholders’ equity (deficit): Common stock, $0.0001 par value, 490,000,000 and 28,500,000 shares authorized at December 31, 2018 and 2017; 36,829,857 and 7,936,434 shares issued and outstanding at December 31, 2018 and 2017, respectively.......................................................................................................... 4 1 Additional paid-in capital............................................................................................. 197,595 584 Accumulated deficit ..................................................................................................... (110,766) (69,323) Total stockholders’ equity (deficit)................................................................... 86,833 (68,738) Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) .................................................................................... $ 92,189 $ 3,244 The accompanying notes are an integral part of these consolidated financial statements.